Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.92

€4.92

3.800%
0.18
3.800%
-

-

 
11.12.25 / Frankfurt WKN: 885825 / Name: ImmuCell / Stock / Biotechnology & Medical Research / Micro Cap /
Your prediction

Immucell Corp Stock

Immucell Corp dominated the market today, gaining €0.18 (3.800%).

Pros and Cons of Immucell Corp in the next few years

Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Immucell Corp vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Immucell Corp 3.800% 9.333% -8.037% 10.314% 4.237% -22.520% -1.205%
Larimar Therapeutics Inc. 3.660% 8.974% 18.056% -40.351% -8.602% -5.028% -81.027%
Vaxart Inc. -0.710% -0.639% -0.356% -49.821% -58.457% -71.193% -95.333%
Achieve Life Sciences Inc. -2.030% -2.889% -4.332% -2.152% 8.415% 59.975% -38.160%

News

ImmuCell Q2 Profit Jumps as Margins Rise
ImmuCell Q2 Profit Jumps as Margins Rise

ImmuCell(NASDAQ:ICCC) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million

ImmuCell Posts 18% Gain in Q2
ImmuCell Posts 18% Gain in Q2

ImmuCell (NASDAQ:ICCC), a specialist in animal health products for the dairy and beef industries, issued its earnings results for the second quarter of fiscal 2025 on August 14, 2025. The company